Been watching this one for a while now, and I must say the latest data from the spinal cord injury model made me sit up and pay more attention..
Two key outcomes bode well for the neuroprotective and possibly neuro-regenerative potential of EmtinB: 1. Increased neurite outgrowth (they even recorded the longest axonal growth ever seen in this model..) 2. Increased synaptic connections Both were increased relative to active comparator, Copaxone, and reached statistical significance..
Targeting this common pathway shared by neurodegenerative diseases opens up a realm of potential indications.
Looking forward to seeing the rabbit ophthalmology data from Lions Eye Institute. Should they be able to demonstrate EmtinB can penetrate the optic nerve post intra-ocular injection, it will support that the drug can be effectively delivered in man for ophthalmology conditions like glaucoma etc. Would tick another major box!
Lots to look forward too. Mice CVN Alzheimers model data to come out shortly too; as well as pre-clin toxicology data. This has to be one of the most exciting and promising early stage CNS assets in development. I'm not surprised to hear that the Company received a lot of interest from big pharma at the recent BIO international conference in the US.
GLTA holders..
A.
NSB Price at posting:
23.0¢ Sentiment: Buy Disclosure: Held
